Menu Search
Equities

Sotera Health Co

SH5:MUN

Sotera Health Co

Actions
  • Price (EUR)14.70
  • Today's Change-0.50 / -3.29%
  • Shares traded--
  • 1 Year change+21.49%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 16:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. The Nordion business is a provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and materials industries and for the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

  • Revenue in USD (TTM)1.12bn
  • Net income in USD70.49m
  • Incorporated2015
  • Employees3.00k
  • Location
    Sotera Health Co9100 South Hills BlvdSuite 300, Suite 300BROADVIEW HEIGHTS 44147United StatesUSA
  • Phone+1 (440) 262-1410
  • Fax+1 (302) 636-5454
  • Websitehttps://soterahealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.